TransMedics Group Inc

TMDX

Equity

ISIN null / Valor 47361695

NASDAQ (2025-11-14)

USD 115.01-0.47%

TransMedics Group Inc
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

TransMedics Group Inc is a company that offers technology and clinical services aimed at improving heart and lung transplant procedures. Their flagship product, the TransMedics Organ Care System (OCS™), is the only FDA-approved technology for lung, heart, and liver transplantation in the U.S. The company's solutions are designed to maximize transplant volume, improve clinical outcomes, and reduce learning curves for medical professionals.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Total revenue reached $157.4 million in Q2 2025, marking a 38% increase compared to Q2 2024. This growth was driven by both net product and service revenues, underscoring the expanding demand for TransMedics' offerings.

Profitability

The company generated a net income of $34.9 million, or $0.92 per fully diluted share, in the second quarter of 2025. This achievement highlights TransMedics' ability to maintain strong gross margins and control operating expenses.

Regulatory Milestone

TransMedics received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial, paving the way for advancements in lung transplant technology.

Product Launch

The company launched its first-in-class OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs in the U.S., enhancing its service offerings and operational efficiency.

Guidance Update

TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting confidence in continued growth and market expansion.

Summarized from source with an LLMView Source

Key figures

30.2%1Y

99.9%3Y

703%5Y

Performance

72.7%1Y

68.2%3Y

72.6%5Y

Volatility